Literature DB >> 15257690

Trousseau's syndrome related to adenocarcinoma of the colon and cholangiocarcinoma.

S-H Tasi1, C-J Juan, M-S Dai, W-Y Kao.   

Abstract

Malignancy-related thromboembolism, so-called Trousseau's syndrome, can present as acute cerebral infarction, non-bacterial thrombotic endocarditis (NBTE) and migratory thrombophlebitis. It is usually attributed to a cancer-related hypercoagulable state, chronic disseminated intravascular coagulopathy (DIC), or tumour embolism. We report on two patients with adenocarcinoma of the colon and cholangiocarcinoma who developed widespread thromboembolism during disease progression. Both did poorly despite aggressive institution of anticoagulation therapy. These cases emphasize that cerebral infarction or refractory thromboembolism in cancer-treated patients should prompt investigation for recurrent or metastatic disease or progression of the underlying malignancy. Optimal treatment remains to be established.

Entities:  

Mesh:

Year:  2004        PMID: 15257690     DOI: 10.1111/j.1468-1331.2004.00814.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  4 in total

1.  Nonbacterial thrombotic endocarditis with recurrent embolic events as manifestation of ovarian neoplasm.

Authors:  Arash Aryana; Dennis J Esterbrooks; Peter C Morris
Journal:  J Gen Intern Med       Date:  2006-09-11       Impact factor: 5.128

2.  Trousseau's Syndrome Caused by Intrahepatic Cholangiocarcinoma: An Autopsy Case Report and Literature Review.

Authors:  Takashi Yuri; Kouta Kato; Y Hirohara; Yuichi Kinoshita; Yuko Emoto; Michiko Yuki; Katsuhiko Yoshizawa; Airo Tsubura
Journal:  Case Rep Oncol       Date:  2014-05-29

3.  Clinical Significance of Prothrombin Time in Cholangiocarcinoma Patients with Surgeries.

Authors:  Hui-Shan Wang; Xian-Xiu Ge; Quan-Peng Li; Jun-Jie Nie; Lin Miao
Journal:  Can J Gastroenterol Hepatol       Date:  2019-07-01

4.  Trousseau's syndrome in association with cholangiocarcinoma: positive tests for coagulation factors and anticardiolipin antibody.

Authors:  Jeong Won Jang; Chang Dong Yeo; Jin Dong Kim; Si Hyun Bae; Jong Young Choi; Eun Sun Jung; Sung Eun Rha; Jae Young Byun; Seung Kew Yoon
Journal:  J Korean Med Sci       Date:  2006-02       Impact factor: 2.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.